PET imaging of prostate-specific membrane antigen in prostate cancer: current state of the art and future challenges

• Published in: Prostate cancer and prostatic diseases 2016-09, Vol.19 (3), p.223-230
• Main Authors: Rowe, S P, Gorin, M A, Allaf, M E, Pienta, K J, Tran, P T, Pomper, M G, Ross, A E, Cho, S Y
• Format: Article
• Language: English
• Subjects: 59/78; 692/53/2421; 692/699/67/589/466; Antibodies; Antigens; Antigens, Surface - metabolism; Biomedical and Life Sciences; Biomedicine; Cancer Research; Care and treatment; Cell surface; Clinical trials; Combined Modality Therapy; Genetic aspects; Glutamate Carboxypeptidase II - metabolism; Health aspects; Humans; Lymph nodes; Male; Medical imaging; Membranes; Metastases; Metastasis; Molecular Imaging - methods; Neoplasm Metastasis; Neoplasm Staging; Oncology; Patients; PET imaging; Positron emission; Positron emission tomography; Positron Emission Tomography Computed Tomography; Positron-Emission Tomography - methods; Prostate cancer; Prostate-specific antigen; Prostatic Neoplasms - diagnosis; Prostatic Neoplasms - metabolism; Prostatic Neoplasms - therapy; Radiation; Radioactive Tracers; Radioisotopes; Radiopharmaceuticals - chemistry; Recurrence; review; Tomography; Treatment Outcome; Urology
• ISSN: 1365-7852; 1476-5608
• DOI: 10.1038/pcan.2016.13

Background: Prostate-specific membrane antigen (PSMA) is a cell surface enzyme that is highly expressed in prostate cancer (PCa) and is currently being extensively explored as a promising target for molecular imaging in a variety of clinical contexts. Novel antibody and small-molecule PSMA radiotracers labeled with a variety of radionuclides for positron emission tomography (PET) imaging applications have been developed and explored in recent studies. Methods: A great deal of progress has been made in defining the clinical utility of this class of PET agents through predominantly small and retrospective clinical studies. The most compelling data to date has been in the setting of biochemically recurrent PCa, where PSMA-targeted radiotracers have been found to be superior to conventional imaging and other molecular imaging agents for the detection of locally recurrent and metastatic PCa. Results: Early data, however, suggest that initial lymph node staging before definitive therapy in high-risk primary PCa patients may be limited, although intraoperative guidance may still hold promise. Other examples of potential promising applications for PSMA PET imaging include non-invasive characterization of primary PCa, staging and treatment planning for PSMA-targeted radiotherapeutics, and guidance of focal therapy for oligometastatic disease. Conclusions: However, all of these indications and applications for PCa PSMA PET imaging are still lacking and require large, prospective, systematic clinical trials for validation. Such validation trials are needed and hopefully will be forthcoming as the fields of molecular imaging, urology, radiation oncology and medical oncology continue to define and refine the utility of PSMA-targeted PET imaging to improve the management of PCa patients.